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ABSTRACT 
The melanin-concentrating hormone receptor- I (MCHR-1) is a member of the 
G protein-coupled receptor (GPCR) superfamily, and functions in the regulation of food 
consumption and energy metabolism. MCHR-1 is expressed in neural, pancreatic, and 
fat tissue. Fat cells begin their journey as pre-adipocytes, culminating in the formation of 
mature adipocytes as differentiation occurs. Of interest to note, fat cells accumulate 
caveolae markers - caveolin-1 and cholesterol - during this process. Certain GPCRs and 
their associated downstream signaling molecules co-localize with caveolae membranes. 
This thesis seeks to demonstrate that MCHR-1 is enriched in lipid rafts and that a 
possible consequence of this may be altered signal transduction in obese individuals, such 
as downregulated ERK.112-mediated leptin transcription. Increased amounts of adipose 
tissue, and thus caveolae, may play a central role in th.e regulation ofMCHR-1 signaling. 
The first aim of this project addressed the question ofMCHR-1 localization to lipid rafts. 
To test this, caveolae membranes were isolated via sucrose density gradient 
u 
1tracentrifugation. Subsequent fractionation and western blotting confirmed that 
MCHR-1 is enriched in lipid raft fractions containing caveolin-1. The second objective 
assessed ligand dependence on MCHR-1 localization. MCH exposure (1 .0-µ.M) had no 
obvious effect on receptor localization to lipid raft fractions containing caveolin-1 over 
an expanded time course. The third aim examined the effect of lipid rafts on MCHR-1 
signaling. Pharmacological disruption of caveolae by cholesterol depletion with methyl-
P-cyclodextrin (MPCD) dampened MCH-mediated ERK.1/2 activation, suggesting that 
lipid rafts may significantly impact the regulation ofMCHR-1 signaling in cells. 
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INTRODUCTION 
Obesity 
The Centers for Disease Control (CDC) estimates that at least 34% of 
American adults were obese in 2006, and that this trend is steadily increasing (I). 
Obesity is present when an individual has an excess amount of adipose tissue, due to 
increased caloric intake and reduced energy expenditure. The medical community 
diagnoses an obese state when an individual has a body mass index (BMI) of 30 or 
higher. Body mass index calculations are based on a person's weight to height ratio. The 
side effects of obesity have been well-documented and include: type II diabetes, sleep 
apnea, stroke, cancer, heart disease, hypertension, dyslipidemia, and osteoarthritis. Most 
recently, several theories have been developed to explain the relatively recent 
phenomenon of prevalent adult and childhood obesity. The CDC suggests that a 
combination of food consumption behaviors, lack of physical activity, environment, 
genetics, and underlying medical conditions are responsible (1). 
Molecular appetite regulation mechanisms are complex and involve interplay 
between hormonal and neural signals, moderated by feedback loops (rev 2). The central 
nervous system (CNS), particularly the hypothalamus, has been implicated as a key 
source of systemic hunger signals. Specifically, the hypothalamus releases a variety of 
neuropeptides, such as neuropeptide Y (NPY), agouti-related peptide (AGRP), galanin, 
melanocortins, glucagon-like peptides, corticotropin releasing factor (CRF), orexin, 
serotonin, and neurotensin. The peripheral nervous system (PNS) has been shown to 
interact with the feeding centers of the brain, through gastrointestinal, hepatic, and 
pancreatic-secreted hormones, including ghrelin, peptide YY, cholecystokinin (CCK), 
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leptin, amylin, insulin, and bombesin as shown in Figure 1 (Appendix I). Appetite 
signals are initially released by peripheral tissues, and are received by the hypothalamus. 
The hypothalamus then secretes additional hormones that prompt an individual to eat. 
Peripheral responses are generated by gastrointestinal organs, such as the large intestine 
and stomach, and by metabolic regulators, such as adipose tissue and pancreatic ~ cells, 
that loop back to the brain to shut off the hunger signal (3). 
The relationship between overeating and obesity appears obvious, but fails to 
address why obese individuals continually feel the need to eat despite high caloric diets. 
The "thrifty genotype hypothesis" suggests that excess intake of high fat, high 
carbohydrate food sources have been evolutionarily selected for (3.4). In the past, 
humans experienced periods of famine and food deprivation. Those who had the ability 
to continue eating during times of provisional availability would have been conferred 
with a selective advantage (4). However, uncontrolled or malfunctioning cellular 
signaling may also lead to dysregulation of the hunger-satiety pathway. An underlying 
genetic abnormality, epigenetic changes in gene expression, or alterations of normal 
cellular functioning may play a role in modulating signaling in the complex neural-
endocrine appetite pathway. Any form of molecular defect may offer a possible 
explanation for the increasing propagation of a global obese population. 
Appetite hormones use G protein-coupled receptors to elicit intracellular responses 
Appetite hormones, such as NPY, orexin, and neurotensin, bind to G protein 
coupled receptors to induce cellular and systemic responses (2). G protein-coupled 
receptors (GPCRs) are characterized by their seven hydrophobic, transmembrane 
spanning domains and association with guanosine nucleotide-binding proteins (G 
3 
proteins) as second messengers (5). GPCRs interact with large, heterotrimeric G proteins 
composed of three individual subunits - a, p, and y (6). The a- and y-subunits are 
tethered to the plasma membrane by short, modified lipid tails. In the inactivated state, 
ligand is absent, and the a-subunit is bound to guanosine diphosphate (GDP). When the 
appropriate ligand - hormone, stimulus, or other peptide - binds to the receptor at the 
plasma membrane, a conformational change occurs within the receptor. This molecular 
signal is passed onto the a-subunit of the G protein, and the a-subunit loses its affinity for 
bound GDP. The a-subunit switches GDP for guanosine triphosphate (GTP), and GTP 
binds the a-subunit in the GPCR activated state. The P- and y-subunits are bound 
together in an obligatory complex. The a-subunit dissociates from the ~-'Y complex, 
whereby both the a-subunit and the P-r complex can contact downstream signaling 
molecules. 
G proteins can elicit a wide array of intracellular signaling cascades. These 
signal transduction pathways dictate tht: particular cellular response that will occur. Well 
documented pathways include the following: Gs1i G0 , and Gq proteins may be activated 
following GTP binding, and each individual G protein acts on a target pathway as shown 
in Figure 2 (Appendix I). Gs stimulates adenylyl cyclase, cyclic AMP ( cAMP), and 
protein kinase A (PK.A). Gi works antagonistically to Gs, and inhibits adenylyl cyclase 
activation and its associated downstream signaling events. Gq activates phospholipase C 
(PLC), which leads to the activation of inositol triphosphate (IP3) , diacylglycerol (DAG), 
and calcium (Ca +2). DAG and Ca +2 work synergistically to initiate protein kinase C 
(PKC) activation. Go protein alone may also trigger the PKC pathway. PKC 
phosphorylates Ras, which signals to Raf and the mitogen-activated protein kinase 
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(MAPK) pathway. The end result of GPCR signal transduction is often a change in gene 
regulation, and ultimately, transcription. 
If a sustained cellular signal is prolonged, its receptor may undergo 
desensitization (5) to "shut off' the activated pathway by failing to respond to the 
presence ofligand (7). The receptor becomes phosphorylated by its respective G protein 
coupled receptor kinase (ORK) on the intracellular C-terminal tail that would otherwise 
interact with Ga (7 ,8). This molecular event creates a binding site for P-arrestin. Once 
P-arrestin is bound, the G protein can no longer associate with the receptor C-terminus 
tail, which terminates downstream signaling. Desensitization to ligand is one mechanism 
by which receptors are downregulated from the cell surface (9). Internalization of 
membrane receptors may also reduce or eliminate a signal transduction response. Areas 
containing receptors along the plasma membrane may form vesicles and remove 
receptors from the cell surface through endocytosis events. Thus, less receptor is 
available for ligand binding, and subsequently, signal transduction is altered. Receptor 
desensitization and internalization may occur independently, or desensitization may 
precede internalization (8). 
Following receptor internalization, which decreases the number of receptors 
available at the cell surface, intracellular trafficking then occurs (I 0). The receptor may 
be targeted to early endosomes for degradation in the lysosomes or for recycling back to 
the plasma membrane (8) as shown in Figure 3 (Appendix I). Receptors, such as the ~ 1-
adrenergic receptor, may be internalized through clatbrin- coated pits or through 
caveolae, depending on the kinase that phosphorylates the C-tenninus (11 ). For the 
transforming growth factor-P receptor (TGF-P-R), the pathway of internalization 
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determines the intracellular fate of the receptor (12). If clathrin targets TGF-P-R, then the 
receptor is recycled for continued signaling. However, the caveolae pathway directs 
TGF-P-R for degradation. 
Certain GPCRs, such as the type I angiotensin receptor, utilize the clathrin 
pathway (112). Clathrin-coated pits are transported from the endoplasmic reticulum (ER) 
to the cytosolic surface of the plasma membrane and assemble into a lattice, creating a 
clathrin-coated vesicle (CCV) with the help of adaptor proteins, such as the AP-2 
complex and dynamin at the neck of the vesicle (6,10,13). The pits then 'pinch off' from 
the plasma membrane, with their molecular cargo secured inside the formed vesicle as 
shown in Figure 4A (Appendix I) (10). Shortly after entering the cell, CCVs lose their 
clathrin coats, and fuse with early endosomes for sorting (13). Recent studies have 
suggested that specific amino acid sequences, such as di-leucine and tyrosine-based 
motifs, may target specific cargo to clathrin-coated pits. 
Lipid rafts and caveolae 
Another possible internalization pathway involves caveolae lipid rafts. Lipid 
rafts form highly ordered, yet adaptable, platforms within the plasma membrane bilayer 
(14). Rafts are dynamic plasma membrane structures composed of proteins, 
sphingolipids, phospholipids, and cholesterol that are assembled in the Golgi complex 
(14, 15). Cholesterol is a key component in the formation of lipid rafts, and is viewed as 
the "glue" that "keeps the raft assembly together" (16). The removal of cholesterol from 
the lipid raft structure and the plasma membrane by phannacological agents causes a 
dissociation of proteins from the lipid rafts, rendering them non-functional. Proteins that 
assemble within the lipid raft complex are dependent upon their association with these 
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detergent-resistant membranes (DRMs) (17). Caveolae are a subset of the lipid raft 
membrane microdomains characterized by the presence of caveolin. 
G protein-coupled receptors and their associated G protein subunits have been 
isolated in lipid rafts and caveolae (18-20). The muscarinic cholinergic receptor and its 
Gaq and the adenosine Al receptor and its Gl!Y subunits have been localized to caveolae 
(20). The role of caveolae and its effects on GPCR signaling have been hypothesized, 
although the exact mechanisms through which caveolae modulates GPCR signaling, 
internalization, and trafficking are still under investigation (21). Caveolae have been 
implicated as a potential mediator of GPCR signal transduction and as an anchor for 
second messengers (19). 
Caveolae were initially observed in endothelial cells by George Pallade in 
1953, with the aid of electron microscopy (EM) as shown in Figure 4B (Appendix I) (22). 
Pallade termed these 50-100-nm invaginations of the plasma membrane, 'plasmalemmal 
vesicles,' due to their budding capacity from the plasma membrane for intracellular 
endocytosis and transport. The integral membrane protein caveolin has been identified as 
the molecular marker of caveolae lipid rafts (23). The most prevalent isoform of caveolin 
is caveolin-1 ( cav-1 ), and is found throughout adipose, fibroblast, smooth muscle, and 
endothelial cells (24,25). Caveolin-2 (cav-2) is also found in the same tissues as cav-1 
(rev 26). Caveolin-3 ( cav-3) has been exclusively localized to smooth, skeletal, and 
cardiac muscle (rev 27). However, caveolin-1 will be discussed, unless otherwise 
mentioned, from this point forward. 
As stated previously, lipid raft regions of the plasma membrane are rich with 
sphingolipids, phospholipids, cholesterol, and membrane proteins. Caveolae lipid rafts 
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are identified as such due to the presence of caveolin. The gene for caveolin-1 localizes 
to chromosome 7 (7q31. l ), a suspected tumor locus (28). Biochemically, cav-1 directly 
binds cholesterol in such a way that allows both the amino and the carboxy termini to 
face the interior of the cytoplasm (29,30). A 33-amino-acid hydrophobic domain anchors 
cav-1 into the plasma membrane. Caveolin is palmitoylated at cysteine residues 134, 
144, and 157 (30,31 ). Caveolae are abundant with G proteins and their receptors, 
signaling molecules, glycosylphosphatidylinositol- (GPI) anchored proteins, and other 
downstream signaling targets (32). Actin, myosin, adenylyl cyclase, PKC, MAPK, and 
DAG are only a handful of the molecules enriched in caveolae membranes. Co-
localization of molecules within caveolae is determined by fractionation methods that 
isolate caveolae membranes. Distinct fractionation of caveolae is possible because the 
density of the caveolar fraction is very light compared to the bulk of the plasma 
membrane (33). It has been hypothesized that caveolae may also behave as a scaffolding 
domain within the cell membrane, allowing for the necessary interactions between 
signaling molecules to occur (34). 
Caveolae are also involved in non-coated pit-mediated internalization events 
(35). Sharma et al. proposed that the balance between cav-1, cholesterol, and 
glycosphingolipids (GSLs) may regulate caveolar endocytosis at the plasma membrane 
(36). Way and Parton maintain that caveolar budding for endocytosis events is a plausible 
mechanism as well (3 7). Clearly, cholesterol plays a distinct function in mediating 
caveolar endocytosis. Cholesterol depletion from the plasma membrane by 
pharmacological agents, such as methyl-P-cyclodextrin, filipin, or nystatin (38), interferes 
with caveolar endocytosis by inhibiting vesicle formation (32). Caveolae are 
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disassembled following cholesterol depletion (39), hindering internalization and 
trafficking. It is important to note that the protein dynarnin, which also associates with 
clathrin-coated pits, is necessary for caveolae budding and fission from the plasma 
membrane during these events ( 40,41). 
It has been suggested that the actin cytoskeleton has a role in regulating 
caveolar endocytosis. Mundy and colleagues conducted a study that examined the 
trafficking of GFP-tagged cav-1 in a Chinese hamster ovary (CHO) cell model (34). 
Without stimulation, GFP-cav-1 was observed to be present at the cell surface within 
invaginated caveolae and near centrosomal regions of the cell in caveosomes. 
The administration of the actin depolymerizing drug latrunculin A resulted in the rapid 
movement of caveolin-associated vesicles towards the interior of the cell, near the 
centrosomes. Caveolae have been observed in three different contexts: first, at the cell 
surface tethered with actin; second, near centrosomal caveosomes intracellularly; and 
third, as components of cavicles, or caveolar vesicles. Cytoskeletal components actin and 
micro tubules influence caveolae, and thereby, may affect GPCR signaling components as 
well ( 42). Thus, both cholesterol and actin play critical roles in maintaining caveolae and 
its functions. 
Melanin-concentrating hormone 
Melanin concentrating-hormone (MCH) was originally isolated in the teleost 
fish, where it was demonstrated to have effects on skin pigmentation (rev 43). Teleost 
fish secrete MCH as an adaptive response to environmental stimuli and stress. The result 
is an overall lightening of color in the scales of the fish. MCH was also found to be 
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present in the pituitary glands of salmon ( 44 ), wherein it was hypothesized to exert 
similar effects. 
The cyclic MCH fish peptide is 17-amino acids in length ( 44 ). A disulfide 
bond forms the ring structure, creating a dicysteine bridge that links residues 4 and 13 
(Cys 7 and Cys16 in mammals) ( 44-46). Matsunaga et al. deemed the cyclic nature of 
MCH to be essential to its biological functioning ( 45). A mammalian MCH homologue 
exists in humans, rats, mice, rabbits, and dogs, shown in Figure 5 (Appendix I) (43,46). 
The mammalian MCH peptide is identical in all of these species, as evident by a 
conserved primary amino acid structure (43). However, there are differences in primary 
amino acid structure between the fish and the mammalian MCH variants. Mammalian 
MCH is 19-amino acids in length, with two additional residues and four substituted 
residues - an N-terminal phenylalanine (Phe18) and aspartate (Asp19) - not observed in 
the fish homologue (46,47). The mammalian MCH peptide will be discussed from this 
point forward unless stated otherwise. 
MCH is one of several protein products derived from the preprohonnone 
MCH (pMCH) gene (48). Post-translational processing of the pMCH peptide may result 
in multiple gene products, including neuropeptide E-I (NEI) and neuropeptide G-E 
(NOE). NEI has been shown to act antagonistically to MCH and agonistically to 
melanin-stimulating hormone (MSH) in cell culture studies (49). MCH promotes feeding 
behaviors, while NEI and MSH inhibit feeding (44). The role of NOE remains to be 
elucidated (49). The human pMCH gene is located at 12q23-24 on the long arm of 
chromosome 12 as seen in Figure 6 (Appendix I) (43). pMCH is 165-amino acids in 
length, and generates MCH following proteolytic cleavage at arginine residues 145 and 
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146 ( 48). In humans, MCH mRNA expression is restricted to the lateral hypothalamus 
and pancreas (50,51). 
A role for MCH has been established in the regulation of pathways involved 
in appetite motivation and energy expenditure (52). MCH peptide synthesis occurs in 
magnocellular neurons and in the lateral hypoth.alamus and zona incerta ( 46). Previous 
studies associated the location of the MCH peptide within both the central nervous 
system (CNS) - the hypothalamus - and the peripheral nervous system (PNS) - the 
pancreas (51,52). Therefore, MCH may act through a systemic mechanism involving 
hunger responses and energy output. The CNS and the hypothalamus, in particular, have 
been implicated as centers of feeding, energy homeostasis, and body weight regulation 
(44,53). The hypothalamus is a key neural area where the CNS communicates with the 
periphery (53). In addition, the hypothalamus is one of the only areas of the brain where 
the blood-brain barrier is absent, conferring a unique potential for peripheral influence. 
MCH mouse models 
Early evidence for the role of MCH in feeding behavior was derived from the 
Maratos-Flier lab' s leptin ob-lob-knockout (KO) mouse (54). Leptin (ob) is the satiety 
hormone that allows an individual to feel ' full' after a meal. ob-lob- mice demonstrate 
elevated levels of MCH mRNA and overexpression of the mature peptide. Deletion of 
leptin appears to be coupled with a marked overexpression of MCH. Ob-lob-mice are 
characterized by obese phenotypes compared to control mice; this is most likely due to 
MCH-induced hyperphagia (50,54). The authors of the study also administered MCH by 
central hypothalamic injection into rats, which resulted in excessive feeding behaviors 
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compared to controls (54). Control mice were observed to have higher MCH mRNA 
expression patterns under fasting conditions. 
Shimada and colleagues engineered a pMCF- KO mouse model (55). These 
mice are characterized by lean phenotypes with 25-30% less body fat than controls. 
pMcw- mice are also shown to be hypophagic with increased metabolic rates, increased 
resting energy expenditures, and low levels of circulating leptin. Similarly, a transgenic 
pMCH overexpressing mouse model was created (56). When given a normal diet, pMCH 
mice were found to be mildly obese and hyperphagic with signs of insulin resistance. 
However, pMCH mice became markedly obese on a high fat diet with symptoms of 
hyperinsulinemia and islet cell hyperplasia, compared to controls. This is consistent with 
the role for MCH as an appetite stimulating hormone. The accumulation of excess body 
fat in the pMCF- mouse also has a negative effect on ~he body's response to insulin 
secretion. Although caloric intake is high, cells of the body fail to absorb circulating 
glucose from the bloodstream. This suggests the possibility of an interaction between the 
absence of MCH and a malfunction of the insulin response. 
Segal-Lieberman et al. produced a double null leptin-deficient ob-lob- MClf1-
mouse as observed in Figure 7 (Appendix I) (50). The double KO shows a dramatic 
reduction in overall body fat compared to the ob-lob-mouse, but with similar hyperphagic 
behaviors. The ob-lob- MCH-1- mouse also demonstrates increased activity, resting 
energy expenditure, and body temperature. Secondary to this, the double null mouse 
displays a lean phenotype with decreased adiposity and improved glucose tolerance and 
insulin sensitivity. This observation is consistent with the role for a functional interaction 
to exist between MCH and cellular insulin responsiveness. 
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-Studies have also been conducted involving MCH injections into the body and 
regions of the brain other than the hypothalamus. Ito et al. performed chronic infusions 
of MCH in mice, which led to the previously noted characteristics of obesity and 
hyperphagia, along with decreased core body temperature and oxidation of fatty acids in 
brown fat (57). Zheng and associates injected MCH into the fourth ventricle of the rat 
brain (58). Decreases in core body temperature and physical activity were observed. 
Although no effects on feeding behavior were evident, the role for MCH as a mediator of 
energy conservation is apparent. MCH was also injected into the lateral ventricle of the 
brain in rats. Dose-dependent effects upregulated feeding behavior to levels two to three 
times that of controls for up to 6-hours post-injection (43). An investigation carried out 
by Stricker-Krongrad and colleagues concluded that in the obese Zucker rat model, 
circulating plasma MCH levels were higher compare~ to controls (59). 
The MCH KO mouse was further characterized during a study that examined 
the influence of MCH on pancreatic islet cells, conducted by Pissios et al. (51). Earlier 
observations indicated that MCH overexpressing mice exhibited increases in pancreatic p 
cell mass. Pancreatic islet P cells are responsible for insulin secretion. Islet hyperplasia 
was evident in control mice, but not in MCH KO mice when both were fed a high-fat, 
hypercaloric diet, as represented in Figure 8 (Appendix I) ( 51 ). In hwnan and mice 
cultured islet P cells, MCH was found to enhance insulin secretion in a dose dependent 
manner, resulting in altered Ca+2 influx, ERK.112 activation, and Akt phosphorylation. 
Thus, a role for MCH in modulating peripheral insulin responses has become 
increasingly clear. 
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Atle/anin-concentrating Jiormone receptors 
Two MCH receptor isoforms have been identified thus far - MCH receptor- I 
(MCHR-1) and MCH receptor-2 (MCHR-2); both are G protein-coupled receptors. 
MCHR-1 was originally identified as SLC-1/GPR24, an orphan somatostatin-like G 
protein-coupled receptor (GPCR) (60-63). The ligand for SLC-1 was previously 
unknown until Lembo et al. demonstrated that MCH (l .0-nm) activated the orphan 
receptor (60). As previously described, MCH has orexigenic, or appetite-stimulating, 
properties, and has been isolated in the hypothalamus and pancreatic islets. MCHR-1 
mRNA has been isolated throughout diverse areas of the brain and CNS, including: 
hypothalamus, thalamus, olfactory tubercle, hippocampus, cerebral cortex, substantia 
nigra, amygdala, locus ceruleus, and medial nucleus accumbens (53,64,65). Muscle, eye, 
tongue, and adipose tissues are additional areas of~CHR-1 expression. MCHR-1 has 
also been identified in mouse and human pancreatic islet~ cells (51). 
The receptor is highly conserved in rats, mice, and humans (rev 43,66). There 
is 95% identity between the human and mouse variants and 96% identity between the 
human and rat variants (rev 43). In humans, the MCHR-1 gene is localized to 
chromosome 22 (22ql3.3), and the MCHR-1 peptide is 353-amino acids in length. 
MCHR-1 has a classical G protein-coupled receptor structure as shown in Figure 9 
(Appendix I), including seven transmembrane helices, a DRY motif at the end of the 
second intracellular loop, and three potential glycosylation sites at the extracellular N-
terminus (rev 43,67). The DRY (Asp141, Arg142, Tyr143) motif is essential for signal 
transduction, and glycosylation sites are necessary for linking the receptor at the cell 
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surface (rev 43). The intracellular C-terminal tail of the receptor has been identified as 
being important, but not required, for internalization (68). 
MCHR-1 couples to Gi. G0 , and Gq proteins for intracellular signaling events 
(62,70,71). Therefore, MCH binding to MCHR-1 leads to cellular changes in the 
inhibition of cAMP through Gi. increases in IP3 and Ca+2 through Gq, and MAPK 
activation through either Gq or G0 • IfMAPK is triggered via G0 , PKC will also be 
activated; this is not the case if MA.PK is phosphorylated by way of Gq. In addition to 
cell culture models, MCH-induced MCHR-1 coupling to Gi and Gq has also been 
characterized in the rat brain (70). 
Saito et al. investigated the possibility ofMCHR-1 internalization via clathrln 
coated vesicles (68). Acetic acid treatment was performed to inhibit clathrin-mediated 
endocytosis events in HEK293 cells transfected with a Flag-tagged MCHR-1 . Cells were 
exposed to 300-nm MCH for 40-minutes. MCHR-1 internalization was only partially 
inhibited by this treatment (66% inhibition), suggesting that non-clathrin-mediated 
endocytosis was also occurring. However, MCHR-1 internalization was found to be 
dependent on: protein kinase C-mediated phosphorylation of three C-terminal amino acid 
residues (W17, Ser125, Thr342) , P-arrestin-2 binding, and endocytosis by a dynamin 
dependent pathway. 
In addition to MCHR-1, a second GPCR for MCH exists-MCHR-2. 
MCHR-2 has been found to exhibit 38% homology with MCHR-1 , as portrayed in Figure 
10 (Appendix I) (72). The highest sequence similarities exist within the amino acid 
residues of the receptor transmembrane domains of the MCH-binding pocket Although 
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38% amino acid sequence correspondence may seem minimal, MCHR-2 is actually more 
highly homologous to MCHR-1 than any other related GPCR (63). The gene for 
MCHR-2 has been mapped to the long arm of chromosome 6 (6q 16.2-3), and has 
multiple coding regions (63,72). MCHR-2 has been shown to couple to Gq, resulting in 
intracellular Ca+2 release (72). Northern blot analysis and in situ hybridization studies 
performed by Sailer and colleagues confirmed the presence ofMCHR-2 mRNA in areas 
of the brain known for body weight regulation - the arcuate nucleus and the ventral 
medial hypothalamus. MCHR-2 has also been detected in the amygdala, an area of the 
brain known for storing emotional memories (63). These results indicate a role for 
MCHR-2 as an additional mediator of the MCH-feeding response pathway with potential 
involvement in the emotional aspect of food consumption. 
MCHR-1 mouse models 
A study conducted by Kokkotou et al. investigated levels ofMCHR-1 
expression in the leptin-deficient ob-lob- mouse model (73). The absence ofleptin was 
found to negatively regulate MCHR-1 mRNA expression. During leptin deficiency 
(ob-lob-), MCHR-1 mRNA expression increases seven-fold. Exogenous administration 
ofleptin in ob/ob-mice decreases MCHR-1 mRNA levels. However, MCHR-1 mRNA 
fails to change within a 48-hour period of fasting for both ob-lob-and control mice. This 
evidence supports a role for leptin-dependent regulation ofMCHR-1 expression in the 
brain. 
The relationship between leptin and MCHR-1 has been further characterized 
in research conducted by Bradley and colleagues using 3T3-Ll adipocytes (74). MCH 
exposure to rat adipocytes in vitro initiates leptin transcription. Further studies concluded 
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that 1.0-µM MCH exposure in 3T3-Ll cells lead to the activation ofMAPK p42/44, or 
extracellular-related kinase 1/2 (ERKl/2) (70,75). One transcription product ofMCH 
mediated MAPK p42/44 phosphorylation was later identified to be leptin (75). MCHR-1 
expression was also examined between pre-adipocytes and mature, differentiated 
adipocytes. No significant differences in MCHR-1 mRNA levels were observed in either 
the immature or differentiated adipocyte state in the absence ofMCH administration. In 
fully differentiated 3T3-Ll cells, MCH exposure was found to downregulate MCHR-1 
mRNA expression in a time course-dependent manner. It is possible that MCH-mediated 
changes in MCHR-1 levels are the result of internalization or another, still unknown, 
molecular event may be occurring. 
A series ofMCHR-1 KO mice have been created to better understand the 
physiological consequences of receptor deletion. Marsh and associates generated the first 
MCHR-1 KO mouse, which displayed normal body weight with a lean phenotype and 
reduced overall body fat mass, due to hyperactivity and altered metabolism (76). These 
mice also demonstrated hyperphagia with a resistance to diet-induced obesity. A second 
aim of the study examined the effects of chronically administered MCH infusions. 
Control mice showed hyperphagia with mild obesity; this was absent in MCHR-1 KO 
mice. These results suggest that MCHR-1 may potentially negatively mediate systemic 
energy expenditure responses in the body. 
Bjursell et al. further characterized the phenotype of the MCHR-1 KO by 
creating an ob "lob· MCHR-1 ·1• mouse, and by examining the effects of receptor deletion 
on insulin sensitivity in an obese model (77). Following a high glucose meal, the 
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ob-lob-MCHR-1 ·1- mouse developed lower blood insulin levels than its ob-/ob-
counterpart. The authors attributed this to increased insulin responsiveness in the ob"/ob-
MCHR-1 ·1- model, and hypothesized that MCHR-1 affects insulin sensitivity via an 
unknown mechanism that is not dependent on body weight. The double null mouse also 
demonstrated high locomotive activity, leaner body mass, decreased body fat, and altered 
body temperature compared to the obese ob"/ob- model. The authors also noted that 
obesity is a contributing factor towards the development of insulin resistance and type II 
diabetes, and that both conditions can often be reversed due to decreases in body weight. 
The hypothesis of the study was that mutations in ob can lead to obesity and insulin 
resistance/type II diabetes. This study provides further evidence for the accwnulation of 
body fat, and its effects on possible cross-talk between MCHR-1 and cellular insulin 
sensitivity. 
MCHR mutations are linked to obesity 
Mutations may arise within the MCH receptor, creating aberrant cell signaling 
patterns, any of which can potentially lead to obesity. The following studies have 
investigated mutation patterns in MCHR-1 and its effects on obese populations. Gibson 
and colleagues examined MCHR-1 and MCHR-2 for possible relationships between 
receptor gene mutations and obesity phenotypes (78). Test subjects with a history of 
hyperphagia and early onset obesity were selected to have their MCHR-1 and MCHR-2 
genes sequenced. Two MCHR-1 missense variants were identified - Y181H and R248Q 
- that were not present in the nonnal weight control participants. In addition, of the total 
541 white test subjects studied, no significant associations were found between MCHR-1 
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single nucleotide polymorphisms (SNPs) and obesity. However, two non-coding variants 
ofMCHR-2 were discovered. 
A study conducted by Bell et al. researched the MCHR-1 gene sequence 
further for evidence of SNPs and a relationship between early-onset extreme obesity (67). 
The 3.5-kb coding region, including untranslated and intronic regions, plus the 1-kb 
assumed promoter region of the MCHR-1 gene sequence were analyzed in a study 
population of 180 morbidly obese adults and 87 morbidly obese children. Thirty-nine 
SNPs were recognized, seven of which encoded for missense mutations, or amino acid 
substitutions as shown in Figure 11 (Appendix I). One of the identified SNPs - R248Q, 
which had been acknowledged by Gibson et al., was verified to be highly associated with 
early onset obesity. The R248Q mutation exists within the third intracellular loop of 
MCHR-1. This GPCR region is associated with P-arrestin binding and receptor 
downregulation (79,80). Perhaps MCHR-1 fails to undergo desensitization and/or 
internalization in these individuals. The remaining six SNPs were further characterized 
in a sample population comprised of 557 morbidly obese adults and 552 obese children 
(67). An SNP found within the supposed promoter region - rs133068 - demonstrates 
protection against obesity in the children under study. The authors proposed that 
disruption of the promoter may downregulate MCHR-1 gene expression. Low receptor 
levels may decrease the orexigenic MCH response in these individuals. 
Caveolae, insulin, and adipocytes 
Of interest to note, adipocytes, or fat cells, accumulate caveolae as 
differentiation occurs from the pre-adipocyte to the mature adipocyte states (81 ,82). The 
caveolae levels of mature adipocytes may be up to ten times that of the pre-adipocyte 
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(81). In addition, insulin receptors have been localized to adipocyte caveolae (83). Upon 
exposure to insulin, the insulin receptor, a tyrosine kinase receptor, phosphorylates cav-1; 
this results in ERK.1/2 activation in 3T3-Ll adipocytes (84,85). The above findings are 
significant in that adipocytes are also recognized as sources of metabolic regulation 
(86,87). Hormones termed 'adipokines' are key mediators in maintaining the critical 
balance between energy storage and expenditure. 
In addition, insulin is produced by pancreatic islet P cells in response to high 
blood glucose levels (5). An attractive discovery- ca+2 influx in the p cells precedes the 
secretion of insulin (88). Insulin activates insulin receptors in adipocytes, which 
ultimately signal via IP3 for the inhibition of continued food intake (5). A possible 
mechanism for cross-talk to exist between the insulin and leptin receptors has been 
hypothesized. Evidence derived from the caveolin-1 KO mouse model demonstrates an 
alteration of insulin receptor levels (89), which further promotes the possibility for links 
to exist between MCHR-1, caveolae, and insulin signaling. 
Caveolin-1 mouse models 
Caveolin-l KO mice were initially discussed in the literature only several 
years ago, when Drab et al. published an article in Science outlining the consequences of 
cellular caveolae loss (90). In mice lacking the gene for cav-1, caveolae are also 
destroyed. This emphasizes that the presence of cav-1 is critical for caveolar 
maintenance, and that all caveolae are associated with the presence of caveolin proteins. 
Furthermore, caveolar invaginations of the plasma membrane are a result of caveolin 
polymerization. Cav-1 KO mice were studied for further physiological abnormalities, 
particularly in the presence of a high fat diet (91 ). These mice exhibited hyperphagia 
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with a resistance to diet-induced obesity and reduced adiposity. Coincidentally, this 
phenotype is similar to that observed in the MCHR-1 KO model. However, insulin, 
glucose, and cholesterol levels were within normal limits. Circulating blood plasma 
quantities of leptin were decreased. There were noted defects in lipid metabolism and 
adipocyte functioning, as presented by abnormally increased triglyceride and free fatty 
acid levels. The conclusions were drawn that perhaps cav-1 plays a role in 
hyperlipidemia and obesity. 
In addition, cav-1 KO mice demonstrate consistent levels of insulin receptor 
mRNA with that of the control (89). However, actual insulin receptor expression at the 
adipocyte surface is reduced to less than 90% in cav-1-deficient mice. A separate study 
indicated conflicting results with regards to free cholesterol levels in cav-1 knockouts. 
Le Lay and associates suggest that cav-1 is responsible for maintaining cellular 
cholesterol content, due to the absence of detectable cholesterol levels in cav-1 KO mice. 
Cholesterol expression was rescued when the gene for cav-1 was reintroduced into the 
defective mice under an adenovirus promoter. Once cav-1 expression was restored, 
cellular cholesterol levels were restored as well. 
However, skeptics remain unconvinced as to the validity of the conclusions 
drawn by the studies involving cav-I KO mice. The foremost question is, are the 
observed phenotypes a result of the loss of cav-1 gene expression, or do the mice 
physiologically compensate for the loss of cav-1, consequentially causing the apparent 
phenotypes (92)? One such explanation for this phenomenon is the caveolin signaling 
hypothesis, which states that the binding of signaling molecules coupled to G protein 
pathways inhibits transduction. Deletion of caveolin, and subsequent release of these 
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downstream signaling components due to the loss of caveolins, allows signaling 
pathways to be activated without restraint. Knockout model gene deletion induces loss of 
the target gene from all tissues of the body. An siRNA approach has been suggested as a 
method of studying phenotypic alterations due to gene inactivation in a tissue-specific 
manner. 
Signif1eance 
At the present time, little is known about the localization, the internalization, 
and the trafficking ofMCHR-1. Previous work has suggested that MCHR-1 partially 
internalizes by a form of non-clathrin-mediated endocytosis ( 68). MCHR-1 is expressed 
in neural, pancreatic, and adipose tissues. Adipocytes accumulate caveolae markers -
caveolin-1 and cholesterol - during their maturation process. Certain GPCRs and their 
associated downstream signaling molecules localize to, or are enriched in, caveolae 
membranes. The first aim ofthis thesis was to demonstrate that MCHR-1 is enriched in 
lipid rafts.- A possible consequence of lipid raft enrichment may be altered signal 
transduction in obese individuals, such as downregulated ER.Kl/2-mediated leptin 
transcription. The second aim of this thesis was to examine the effect of ligand exposure 
on MCHR-1 localization to lipid raft fractions containing caveolin-1. Receptor 
movement into lipid rafts may indicate the occurrence ofMCHR-1 caveolar-mediated 
endocytosis. The third aim was to disrupt caveolae by pharmacological cholesterol 
depletion to determine the effect of lipid rafts on MCHR-1 signaling pathways, 
particularly the ERK.112 response. This work is significant because the elucidation of 
receptor signaling pathways and meGhanisms proposed to be involved in obesity is 
necessary for potential pharmacological targeting and drug development. 
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MATERIALS AND METHODS 
Cell culture 
Stably expressing VSVg-tagged MCHR-1 CHO-Kl cells were cultured in 
F12k- media (CellGro) containing 5% fetal bovine serum (FBS) and selected with 
0.50-g/mL G-418 (A.G. Scientific). Cell lines were cultivated as monolayer cultures at 
37°C, 95% air, and 5% C02 in a humidified environment. All cells were passaged when 
80-90% confluent. 
Melanin concentrating hormone (MCH) treatment 
MCH (1.0-µM, American Peptide) was added to cells in F12k- media for the 
indicated times. 
Cholesterol depletion with methyl-p-cyclodextrin 
VSVg-MCHR-1 CHO-Kl cells were serum starved overnight or 1-hour prior 
to cholesterol depletion, as specified. Methyl-P-cyclodextrin (5.0-mM or 10.0-mM, 
Sigma) was added to cells in FJ 2k- media for I-hour preceding MCH exposure. 
Cholesterol repletion with soluble cholesterol 
VSVg-MCHR-1 CHO-Kl cells were serum starved in Fl2k- media 1-hour 
prior to cholesterol repletion. Soluble cholesterol (1 .0-mM, Sigma) was added to cells in 
F 12k- media for 1-hour prior to MCH exposure. 
Immunocytochemistry 
Stable VSVg-MCHR-1 CHO-Kl cells were grown to 50% confluency on 
coverslips in 35-m.m clishes. Cells were exposed to MCH for the designated time points. 
1 Performed by Kelsi Robinson, B.S. 
23 
All coverslips were washed twice with 1 x PBS, fixed with 4% paraformaldehyde in PBS 
for IO-minutes, and washed three times with lx PBS. Cells were blocked with 5% goat 
serum/0.1 % Triton X-100 (Sigma) for 20-minutes in a humidified chamber. Blocking 
solution was removed, and rabbit anti-VSV g antibody (1: I 000, Sigma) in blocking 
solution was added for 2-hours to overnight. Cells were washed three times, 5-minutes 
each with lx PBS shaking at room temperature. Anti-rabbit Alexa Fluor 488 antibody 
( 1 :500, lnvitrogen) in blocking solution was added to coverslips for 45-minutes to 1.5-
bours in a dark, humidified chamber. DAPI (1.0-µg/mL, Roche) stain was applied to 
cells for 20-minutes in a dark, humidified chamber. All coverslips were washed with Ix 
PBS for 5-minutes, then washed with d.H20 for 5-minutes shaking at room temperature. 
Coverslips were removed from dishes, and dried at room temperature. ProLong Gold 
(Invitrogen) was applied to coverslips on blank slides and allowed to cure. Clear nail 
polish completed the coverslip mounting. All slides were allowed to dry overnight at 
room temperature in a dark environment. 
Fluorescence and confocal microscopy 
Fluorescence microscopy was carried out using the Zeiss Axiocam MRm 
fluorescence microscope with Axio View imaging software. Confocal microscopy was 
performed with the structured light imaging OptiGrid confocal microscope with Image 
ProPlus software. 
Detergent-free sucrose gradient caveolae isolation 
Stable VSVg-MCHR-1 CHO-Kl cells were cultured to confluency on four, 
100-x-20-mm dishes. The dishes were placed on ice, washed twice with cold Ix PBS, 
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and harvested in 4.0-mL, 500-mM sodium carbonate (pH 11.0) with protease inhibitors 
cocktail (1: 1000, Sigma). Cells were allowed to swell on ice for 30-minutes. Total cell 
lysate was prepared by forty strokes with a chilled, dounce homogenizer. Caveolae 
membrane microdomains were isolated via detergent-free sucrose density gradient 
ultracentrifugation as previously described by others (93) with modifications. Cell lysate 
(2.0-mL) was transferred to a 13-mL ultracentrifuge tube (Beckman). To the tube, 
2.0-mL, 90% sucrose in Mes-buffered saline (MBS; 25-mM Mes, pH 6.5, 0.15-M NaCl) 
was added and vortexed. Carefully and slowly, 4.0-mL, 35% sucrose in MBS with 
250-mM sodium carbonate (pH 11.0), foll~wed by 4.0-mL, 5% sucrose in MBS with 
250-mM sodium carbonate (pH 11.0) was added dropwise to the top of the gradient. 
Gradients were ultracentrifuged at 39,000-rpm for 16-18-hours at 4°C with an SW-41 
rotor. Thirteen fractions (1.0-mL each) were collected from each gradient on ice, and 
100-µL of each fraction was added to 25-µL, 5x Laemelli sample buffer. All remaining 
samples were frozen at -80°C for storage. 
SDS-PAGE 
SOS-PAGE gels (10-12% running gel, 4% loading gel) were prepared as 
described in Appendix III. Samples were boiled for 2-4-minutes, then centrifuged at 
16,000-rpm for 4-minutes. EZ Run™ pre-stained Rec protein ladder (5-µL/lane, Fisher) 
was used as the molecular weight standard. Gels were run at 100-120-volts for 1-2-
hours. SOS gels were removed, and incubated with blotting paper (BioRad) and 
nitrocellulose (BioRad) for 20-minutes in semi-dry transfer buffer. Transfer to 
nitrocellulose occurred at 15-volts OI\ a Trans-Blot® SD semi-dry transfer cell (BioRad) 
for I-hour. 
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Western blotting 
Nitrocellulose blots were blocked for 1-hour at room temperature or 
overnight at 4°C, shaking in 5% dry milk!TBS-T. Primary antibody2 in blocking solution 
with 0.01% sodium azide was added overnight at 4°C shaking. Nitrocellulose 
membranes were washed three times, 10-minutes each with blocking solution, shaking at 
room temperature. Secondary cortjugated-HRP antibody (1 :2000 or 1 :5000) in blocking 
solution was added for 45-minutes to 1.5-hours shaking at room temperature. 
Nitrocellulose membranes were washed three times, 10-minutes each with blocking 
solution, shaking at room temperature. Nitrocellulose was subjected to 1.5-mL oxidizing 
and enhanced luminol solutions of western lighting™ chemiluminescence reagent plus 
kit (Perkin Elmer) for I-minute. Blots were exposed to film (Kodak) and developed 
using developer (Kodak) and fixer/replenisher (Kodak) for varying times3. 
Bradford assay 
The assay was performed using a bovine serum albumin (BSA) standard 
(0-100-µg) for comparison with experimental protein levels. Bradford reagent (1.0-mL) 
was added to each BSA control and vortexed. All samples were transferred to a cuvette, 
blanked, and measured for absorbency in a spectrophotometer OD595 (ThermoSpectronic 
Genesys 10-UV). Bradford reagent (l.O~mL) was added to 100-µL experimental sample 
and vortexed. All samples were transferred to a cuvette, blanked, and measured for 
absorbency in a spectrophotometer OD595 as described. 
2 1 :2000 rabbit anti-VSV g (Sigma), I :5000 rabbit anti-caveolin (BD Biosciences), 1: 1000 rabbit anti-p42/44 
P-MAPK (Cell Signaling), 1: l 000 mouse anti-Total p42/44 MAPK (Cell Signaling). 
3 Typically exposures were taken at 1-, 3-, and 5-min and/or less than 1-min exposures, if needed. 
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Densitometry with Adobe Photoshop 
Western blot images were scanned into the computer. The images were 
converted from color to grayscale, and then inverted. Densitometry was measured with 
control cells reported as the baseline (1.0 relative units). 
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RESULTS 
CHO-Kl cells stably expressing VSVg-tagged MCHR-1: a model system for studying 
MCHR localization 
The data shown in Figure 1 (Appendix II) are representative of two 
immunocytochemistry experiments. MCHR-1 localization and internalization was 
investigated in stably expressing VSVg-MCHR-1 CHO-Kl cells, a mammalian cell 
culture model. Cells were subjected to MCH (1.0-µM) to assess changes in MCHR-1 
localization and internalization following ligand exposure. At 0-minutes MCH exposure, 
MCHR-1 is visualized along the plasma membrane with additional, possibly immature 
receptor found intracellularly near the nuqleus. At 10-minutes MCH exposure, MCHR-1 
partially internalizes from the plasma membrane. This is evident by vesicle formation 
and by an absence ofMCHR-1 membrane staining. The observed staining pattern 
resembles that ofRab5, an early endosomal marker (94). Cellular nuclei are DAPI 
stained in blue. 
MCHR-1 co-localizes with caveolin-1 enriched lipid raft fractions 
The data presented in Figure 2 (Appendix II) are demonstrative of four 
replicated experiments.4 To determine ifMCHR-1 co-localizes with caveolae, caveolae 
membranes were isolated by sucrose density ultracentrifugation and fractionation by a 
detergent-free method with modifications (93). Thirteen fractions were collected from 
the gradient, run on 12% SDS-PAGE gels, and transferred to nitrocellulose. Western 
blotting using antibodies toward VSV g and cav-1 confirmed the presence of VSV g-
MCHR-1 in caveolae fractions 4 and 5. Caveolin-1 localized to fractions 4, 5, 6, and 7, 
which is consistent with the current literature as caveolae is commonly isolated in 
4 Westem blots were assisted by Kelsi Robinson, B.S. 
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fractions 4 and 5 (93). The wider distribution of caveolin-1 enriched fractions relative to 
fractions containing VSVg-MCHR-1 may be explained by the high concentrations of 
cellular caveolae present relative to receptor. This was also observed for the scavenger 
receptor CD36 using a similar caveolae isolation method (129). A Bradford assay was 
performed to evaluate the total protein levels of each fraction from the gradient. 
Caveolar content peaked at fraction 5. The western blot also demonstrated that fraction 5 
contained more VSVg-MCHR-1 and cav-1 than fractions 4, 6, or 7. Fraction 13 fell out 
of range for the standard BSA curve. 
MCHR-1 localization to caveolin-1 enriched fractions is independent of 1.0-µM MCH 
treatment at 10-minutes with equal protein loading 
The results shown in Figure 3 (Appendix II) are representative of three 
experiments. To evaluate the effects ofMCH expos~e on MCHR-1 localiz.ation to 
caveolae, stable VSVg-MCHR-1 CHO-Kl cells were cultured to confluency. Cells 
received MCH (1.0-µM) in F12k.media for 0- or IO-minutes as designated prior to 
harvesting. Caveolae membranes were isolated as previously described (93) with 
modifications, and fractions were removed. A Bradford assay was performed to 
determine the total protein content of each fraction. Equal amounts of protein 
(approximately 100-ng) were loaded onto the gel for fractions 4, 5, 6, and 7 from each 
gradient. SDS-PAGE gels (10%) were run and transferred to nitrocellulose. Western 
blotting with antibodies toward VSVg and cav-1 established that VSVg-MCHR-1 and 
cav-1 localize to both fractions 4 and 5 for each gradient at both 0- and 10-minutes MCH 
exposure. The majority ofVSVg-MCHR-1 and cav-1 localized to fraction 4 and smaller 
amounts to fraction 5 with equal quantities of protein loaded. Trace amounts of VSV g-
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MCHR-1 and cav-1 were present in fraction 6. Neither cav-1 nor VSVg-MCHR-1 was 
present in fraction 7. 
MCHR-1 localization to caveolae lipid raft fractions is independent of MCH exposure 
across time points 
The data shown in Figures 4 and 5 (Appendix II) are representative of one 
experiment5. To establish the effects of varying lengths ofMCH exposure on MCHR-1 
localization to caveolae, VSVg-MCHR-1 CHO-Kl cells received MCH (1.0-µM) in 
Fl2k- media for 0-, 5-, 10-, and 30-minutes as indicated. Caveolae membranes were 
isolated as previously described (93) with modifications, and fractions removed from 
each gradient. SDS-PAGE gels (10-12%) were run for all samples, and transferred to 
nitrocellulose. Western blotting using anti-VSVg antibody towards tagged MCHR-1 was 
necessary to analyze the distribution of receptor across the time points, as seen in Figure 
4A (Appendix II). At 0-minutes MCH exposure, VSVg-MCHR-1 is evident in fraction 4, 
with less receptor in fraction 5 - in between the 55- and 72-kDa molecular weight (MW) 
markers. VSV g-MCHR-1 is found in fraction 4 between the 55- and 72-kDa MW bands, 
and in fraction 5 and 6 with a slight MW upshift at 5-minutes MCH exposure. Following 
10-minutes MCH exposure, VSVg-MCHR-1 is present in fraction 4 near the expected 
MW, and in fraction 5 and 6 with a slight MW upshift. Receptor is observed in fraction 5 
with smaller levels of receptor in fraction 4 at 30-minutes MCH exposure, and the MW 
upshift is absent. 
Western blotting using anti-caveolin antibody towards cav-1 was necessary to 
analyze the distribution of isolated caveolae in each gradient as evident in Figure 4B 
(Appendix II). At 0- and 5-minutes MCH exposure, caveolae was isolated in fractions 4 
s Sucrose gradient performed by thesis author and Laurie Cook, Ph.D. 
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and S, with lesser amounts present in fractions 6-8, and trace amounts in fractions 9-12. 
Small amounts of caveolae were present in fraction 4, with the most caveolae in fraction 
5, followed by fraction 6 at 10-minutes MCH exposure. The majority of the caveolae is 
localized to fractions 4 and S, followed by fraction 6, with trace amounts in fractions 7 
and 8 at 30-minutes MCH exposure. 
A Bradford assay was performed on all the fractions of each MCH time point 
sucrose gradient6. At 0-minutes MCH exposure, protein levels peaked at 0.09S-mg in 
fraction 4, followed by 0.080-mg in fraction S, as shown in Figure SB (Appendix II). 
Protein levels peaked at 0.125-mg in fraction S, followed by 0.085-mg in fraction 4 and 
0.072-mg in fraction 6 at S-minutes MCH exposure, as seen in Figure SC (Appendix II). 
Figure SD (Appendix II) shows that at IO-minutes MCH exposure, protein levels peaked 
at 0.13S-mg in fraction S, followed by 0.08S-mg in fraction 6. Protein levels peaked at 
0.076-mg in fraction 5, followed by 0.065-mg in fraction 6 at 30-minutes MCH exposure, 
as evident in Figure SE (Appendix II). These results were consistent with those observed 
in the corresponding western blots for each MCH time point. 
Manipulation of membrane cholesterol alters the distribution ofMCHR-1 in stably 
transfected CHO-Kl cells 
The data shown in Figure 6 (Appendix II) are representative of one 
immunocytochemistry experiment7. To further explore the possibility ofMCHR-1 
enrichment in caveolae, cellular membranes were deprived of cholesterol with M~CD 
(5.0-mM) or supplemented with exogenous cholesterol (1.0-mM). VSVg-MCHR-1 
CHO-Kl cells were also subjected to MCH (1.0-µM) for indicated time points to 
6 Bradford assay and protein calculations completed by Laurie Cook, Ph.D. 
7 Experiment performed by Kelsi Robinson, B.S. 
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determine changes in receptor localization following hormone treatment. Alterations in 
cellular cholesterol content may modulate MCHR-1 localization to caveolae. The 
reduction of membrane cholesterol levels lead to the destruction of caveolae lipid rafts, 
and the accumulation of soluble cholesterol in the plasma membrane replenish caveolae 
already present. All images were taken for the same exposure time to capture MCHR-1 
internalization following MCH treatment for 0-, 30-, and 60-minutes. In control cells, 
partial receptor internalization is observed at 30-minutes MCH exposure, with possible 
receptor return to the cell surface at 60-minutes. Cells that have undergone cholesterol 
depletion with M~CD demonstrate severe morphological deformities and alterations in 
membrane structure. Cell viability was significantly diminished following cholesterol 
depletion (data not shown), as evidence by the few cells remaining on coverslips during 
microscopy. Due to the observed morphological defects in the cell membrane, it was 
difficult to evaluate evidence ofMCHR-1 internalization following MCH treatments. 
The addition of soluble cholesterol caused MCHR-1 to redistribute itself within the cell. 
MCHR-1 appeared to localize to areas, such the endoplasmic reticulum (ER), 
surrounding the nucleus after 30- and 60-minutes of MCH exposure. The staining pattern 
resembles that of calnexin, an ER molecular marker (95). 
Cholesterol depletion with methyl-p-cyclodextrin dampens MCH-dependent ERK 112 
activation 
The data displayed in Figure 7 (Appendix II) are representative of three 
replicated experiments8. To investigate the effects of cholesterol depletion and caveolae 
disruption on MCHR-1 signaling, transiently transfected CHO-Kl cells expressing 
8 M~CD and ER.Kl/2 experiments performed by thesis author and Laurie Cook, Ph.D. 
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untagged MCHR-1 were grown to confluency in a 12-well dish9• Cells were serum 
starved for I-hour, cholesterol depleted with 10.0-m.M MPCD for I-hour, exposed to 
1.0-µM MCH for the designated times, and harvested. Samples were run on 12% SDS-
PAGE gels, and transferred to nitrocellulose for western blotting with ERKI/2 
antibodies. Total ERKI/2 levels were constant across both cell types. MCH induced a 
peak phosphorylated ERK.1/2 response at 5-minutes and sustained the signal at 10-
minutes exposure in control cells. In MPCD treated cells, activated ERKI/2 appeared at 
5-minutes and was prolonged up to 30-minutes MCH exposure as shown in Figure 7 A 
(Appendix II). 
Densitometry was performed using Adobe Photoshop software10 as shown in 
Figure 7B (Appendix II). Baseline levels (1.0 relative units) of control cells were 
reported. Control cells demonstrated peak ERKI/2 activation at 5-minutes MCH 
exposure with 52 relative units; the signal was sustained at I 0-minutes MCH exposure 
with 42 relative units. Levels of phosphorylated ERKI/2 declined at 30-minutes with 2.0 
relative units. In MPCD treated cells, ERKl/2 activation appeared at 5-minutes with 7.5 
relative units and peaked at l 0-minutes with I 0 relative units. After 30-minutes of MCH 
exposure, P-ERK levels remained at 5.0 relative units. The MCH-dependent ERK.1/2 
response was dampened in cholesterol depleted/caveolae disrupted cells compared to 
controls. 
9 Transfection carried out by Laurie Cook, Ph.D. 
10 Densitometry for this blot was performed by Laurie Cook, Ph.D. 
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DISCUSSION 
CHO-Kl cells stably expressing VSVg-tagged MCHR-1: a model system/or studying 
MCHR localization 
Partial internalization ofVSVg-MCHR-1 was evident following 10-minutes 
MCH exposure in this preliminary immunocytochemistry experiment. The procedure 
was only performed twice so the results should not be considered definite. However, this 
early evidence has suggested that 10-minutes of exposure to 1.0-µM MCH is sufficient to 
cause receptor internalization from the plasma membrane in the stable VSV g-MCHR-1 
CHO-Kl cell model. This is consistent with the literature for MCHR-1 internalization. 
Saito et al. demonstrated that 5-minutes of 300-nm MCH exposure led to 21. 9 +I- 2.6% 
loss of surface receptor, and that 30-minutes of hormone exposure led to 44.2 +;_ 2.5% 
loss of surface receptor (68). 
MCHR-1 co-localizes with caveolin-1 enriched lipid raft fractions 
Fractionation methods using insolubility detergents such as Triton X-100 or 
detergent-free methods such as sucrose gradients are widely used to isolate caveolae and 
lipid rafts from the rest of the plasma membrane and cellular contents (32,93). These 
techniques are successful because the density of caveolar membranes is very light 
compared to the bulk of the plasma membrane (33). In addition, caveolae membrane 
components- glycosphingolipids, GPI-anchored proteins, and caveolin-resist 
solubilization by detergents, giving rise to the term "detergent- resistant" membrane 
microdomains (rev 98). The advantage of sucrose gradient preparation methods include: 
a more delicate membrane preparation and a purer caveolar fraction (93,99). 
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Co-localization and/or enrichment of various signaling molecules or membrane receptors 
within caveolae fractions, following isolation procedures, are an accepted method of 
confirming the presence of these molecules within caveolae. Song et al. established that 
the Ras protein co-localizes with caveolae membranes, along with c-Src, Gua, and Grr, by 
a detergent free, sodium carbonate-based sucrose density gradient method (93). The 
protocol used for identifying the co-localization ofMCHR-1 with lipid raft fractions 
containing caveolin-1 has been adapted from Song et al. 
VSVg-tagged MCHR-1 was found to co-localize with caveolin-1 enriched 
fractions - 4 and 5 - subsequent to sucrose density gradient ultracentrifugation as shown 
in Figure 2 (Appendix II). The majority ofVSVg-MCHR-1 and caveolae were localized 
to fraction 5, as evident by western blot and Bradford assay. A protein peak at fraction 5 
confirmed that caveolae was separated from the remajnder of the cellular contents. Song 
and colleagues observed caveolae localization to fraction 5 in the previously mentioned 
investigation (93). Fractionation methods that isolate caveolae and co-
immunoprecipitation with caveolin are the two approaches discussed in the literature for 
establishing the presence of caveolae enrichment and/or co-localization (20). Thus, 
MCHR-1 was found to be enriched in characteristic caveolin-1 containing fractions as 
demonstrated by caveolar fractionation and western blotting. The same results were 
apparent in each of the four replicative experiments. This provides strong evidence for 
MCH receptor enrichment to lipid raft regions of the plasma membrane. 
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MCHR-1 localization to caveolin-1 enriched fractions is independent of J.0-µM MCH 
treatment at 10-minutes with equal protein loading 
Exposure to 1.0-µM MCH appeared to have no effect on receptor localization 
to caveolin-1 fractions within 10-minutes, with equal amounts of fractionated protein 
loaded onto SDS-PAGE gels as seen in Figure 3 (Appendix II). At 0-minutes and at 10-
minutes MCH exposure, both MCHR-1 and cav-1 remain localized to fractions 4 and 5. 
A hypothesized explanation for this is that the receptor has not yet undergone 
internalization from the plasma membrane and remains within lipid rafts at 10-minutes. 
To test this, a longer time course of hormone treatment was performed to investigate 
whether or not the MCH receptor moved out of lipid raft fractions when exposed to 
MCH. 
MCHR-1 localization to caveolae lipid raft fractions is independent of MCH exposure 
across time points 
An expanded time course, including 0-, 5-, 10-, and 30-minutes ofMCH 
exposure was carried out as observed in Figures 4 and 5 (Appendix II). This experiment 
was only performed once, so the results must be interpreted with the knowledge that 
repetition is necessary to be certain of the outcome. Poor caveolae distribution during the 
0- and 5-minute MCH exposures was most likely due to poor technique in removing the 
fractions off the gradient, rather than an error of the gradient itself. The co-localization 
ofVSVg-MCHR-1 and cav-1 is apparent throughout each point of the MCH time course. 
However, the majority ofMCHR-1 appears to be present in fraction 4 at 0- and 5-minutes 
MCH exposure, with a transition to fraction 6 at 10-minutes, and with a transfer back to 
fraction 5 at 30-minutes as seen in figure 4A (Appendix II). These results may suggest a 
role for lipid rafts in the internalization of MCHR-1. 
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Receptor enrichment to caveolae membranes may or may not be accompanied 
by caveolar endocytosis (rev 8). First, in general, receptor localization to caveolae may 
be coupled with caveolar-mediated endocytosis. Second, opposite to this scenario, 
receptor transition out of caveolae fractions may be evidence of clathrin-dependent 
receptor-mediated endocytosis events (rev 8). Receptors that reside in lipid rafts may 
move into clathrin-coated pits for internalization upon ligand exposure. Third, receptors 
may transition into caveolae lipid rafts for endocytosis following agonist exposure. 
Fourth, ligand administration may prompt other receptors to enter caveolae for signaling 
events, but then later internalize via clathrin·coated vesicles. MCHR-1 does not appear 
to be entirely caveolae-dependent since th.e inhibition of clathrin endocytosis partially 
abolished receptor internalization (68). MCHR-1 has been shown to reside in lipid raft 
fractions containing caveolin-1 as seen in Figure 2 (Appendix II). Thus, MCHR-1 
movement into caveolae is not dependent on MCH exposure. The most plausible 
explanation is that MCHR-1 is enriched in caveolae, and internalization may occur by 
either clathrin-coated pits or lipid rafts. This is the case for the P1-adrenergic and the 
transforming growth factor ~- (TGF ~-) receptors. Dependency on either endocytotic 
pathway may be determined by speci:fidcinase phosphorylation events (11). For the p1 
adrenergic receptor, protein kinase A directs the receptor to caveolae internalization, and 
ORK-mediated phosphorylation targets the receptor to clathrin- coated vesicles. 
Ibe small upshift in MCHR-1 molecular weight may be due to 
phosphorylation of the C-terminal tail of the receptor prior to internalization as seen in 
Figure 4A (Appendix II). G protein-coupled receptors such as the thyrotropin releasing 
hormone receptor (TRHR) are phosphorylated on their C-taiJs before internalization 
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occurs (100,101). A small upshift in molecular weight of the TRH receptor has also been 
observed once it has been phosphorylated (101). The addition of phosphatases reverted 
the molecular weight to that of the mature TRH receptor. The MCHR-1 upshift was 
initially observed at 5-minutes MCH exposure. Confirmation ofMCHR-1 
phosphorylation could be performed using a method similar to that of Zhu et al. with the 
TRH receptor (101 ). Alternative explanations for the change in molecular weight of 
MCHR-1 following ligand treatment include climerization or ubiquitination. GPCR 
dimerization has recently been cited as a common event that enables molecular cross-talk 
to occur between receptor families (102). However, dimerization is probably unlikely as 
it would result in a doubling of the molecular weight rather than only a small upshift as 
was observed. Ubiquitination is also doubtful as this molecular event would produce a 
much larger increase in molecular weight than noted for MCHR-1 (102,103). 
Co-localization of the MCH receptor to lipid raft fractions containing cav-1 
provides strong evidence supporting the presence ofMCHR-1 within caveolae. Although 
MCHR-1 does not appear to move out of caveolae lipid rafts as longer hormone exposure 
occurs, this does not rule out caveolae as a possible mechanism ofMCH receptor 
internalization. The next step would be to assess whether or not MCHR-1 and cav-1 
form a protein complex with each other; this can be achieved through co-
immunoprecipitation studies of isolated caveolae membrane fractions containing 
receptor. IfMCHR-1 and cav-1 do form a protein complex with each other, then 
movement from caveolae membranes would not be as readily apparent in fractionation 
and western blot studies such as those performed. It is also important to note that 
although MCHR-1 appears to localize to caveolae in CHO-Kl cells, the receptor may 
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actually be enriched in caveolae in certain cell types, yet found in other locations of the 
plasma membrane in other cell types. 
Manipulation of membrane cholesterol alters the distribution of MCHR-1 in stably 
transfected CHO-Kl cells 
Cholesterol depletion and repletion techniques are standard procedures used to 
disrupt or restore cellular caveolae, respectively. IfMCHR-1 is enriched in caveolae 
lipid rafts, and cholesterol levels are manipulated, internalization, trafficking, and 
receptor signaling will subsequently be affected. lmmunocytochemistry was utilized as a 
means to evaluate cholesterol depletion and repletion on MCHR-1 internalization. This 
preliminary experiment was only performed once, so the results must be considered with 
this in mind. No conclusions can be made regarding the effect of cholesterol depletion, 
and subsequent destruction of caveolae, onMCHR-1 internalization. Imaging ofVSVg-
MCHR-1 CHO-Kl cells, following M~CD treatment, shows a severely deformed cellular 
structure. There were very few cells to image post-M~CD. Immunocytochemistry 
studies with cholesterol depletion were not a good method of confirming MCHR-1 
localization to caveolae lipid rafts. An alternative may be to perform 
immunocytochemistry with fluorescence-tagged antibodies to establish co-localization 
between MCHR-1 and caveolin-1. Fluorescence imaging, a widely established approach, 
has been used to assess the co-localization of molecules in vitro. Often, green and red 
fluorescence-conjugated secondary antibodies are used towards the two proteins of 
interest. Co-localization may be observed if the two fluorescent antibodies overlap, 
producing yellow fluorescence. 
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The addition of soluble cholesterol appears to redistribute MCHR-1 compared 
to control cells. At 30- and 60-minutes post-MCH exposure, MCHR-1 is observed to 
internalize to areas surrounding the nucleus. This differs from control cells since this 
form of receptor relocation is not evident. These areas are hypothesized to be 
endoplasmic reticulum (ER). Further studies involving immunocytochemistry aimed at 
determining co-localization of MCHR-1 and molecular markers of the ER in cholesterol 
repleted cells would be necessary to verify this finding. Organelle markers that could be 
utilized include calnexin, an ER marker involved in protein folding (95). 
Cholesterol depletion with methyl-p-cyc;lodextrin dampens MCH-dependent ERK 112 
activation 
Cholesterol depletion with methyl-P-cyclodextrin (MPCD) disassembles 
caveolae lipid rafts. If MCHR-1 were enriched in caveolae, lipid raft disruption would 
subsequently be expected to alter receptor signaling. MCHR-1 activates ERKl/2 via G0 
with protein kinase C, or Gq with calcium release (62). The phosphorylated ERK.112 
response in cholesterol depleted cells was dampened and peaked later than the control 
cell response. These results suggest that caveolar destruction downregulates MCHR-1 
mediated ERKl/2 activation. Similar results were observed over the course of four 
repeated experiments, both with stable and transiently transfected MCHR-1 expressing 
CHO-Kl cells; and thus, can be considered valid. 
Previous studies that did not involve MCH or MCHR-1 demonstrated 
hyperactivation ofERKl/2 (p42/44 MAPK) as a by-product of membrane cholesterol 
depletion and caveolar loss (28,97). Cholesterol depletion with pharmacological agents 
is often utilized as a technique for disrupting caveolae lipid rafts during experimental 
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analysis. Hyperactivation of the p42/44 MAPK cascade was observed in at least two 
separate investigations. Furuchi et al. noted phosphorylated ERK overexpression 
following cholesterol depletion with cyclodextrin in rat-1 cells (97). The study indicated 
that membrane cholesterol levels may also order the molecular components of signal 
transduction cascades. It was hypothesized that interference with membrane cholesterol 
may lead to cellular disorganization and dysregulated signaling patterns. Galbiati and 
colleagues documented hyperactivation of p42/44 MAPK following siRNA knockout of 
cav-1 in NIH 3T3 cells (28). This work theorized that cav-1 may negatively regulate the 
p42/44 MAP kinase (ERKl/2) pathway. 
lfMCHR-1 were enriched in lipid rafts, cholesterol depletion would be 
expected to disrupt the lipid raft scaffolding domain and alter signaling by reducing the 
availability of downstream targets. Thus, the signaling response ofMCHR-1 would be 
predicted to decrease following cholesterol depletion. The data presented in Figure 7 
(Appendix II) indicate a role for MCHR-1 enrichment to lipid rafts. Downregulated 
phosphorylated ERK.112 levels suggest that such events are likely occurring due to 
MCHR-1 enrichment in raft regions. Hyperactivation of the p42/44 MAPK cascade is 
absent, indicating that the results obtained are due to MCH-dependent ERK.112 responses 
rather than an anomalous consequence of lipid raft disassembly. 
Interestingly, ERKl/2 activation was previously shown to induce leptin 
transcription in 3T3-Ll cells (74). Leptin acts as an appetite suppressor, while MCH 
stimulates feeding and energy conservation. A role for lipid raft regulation ofMCHR-1 
signaling is plausible, as demonstrated by the functional ERK.112 signaling data presented 
in this thesis. IfMCHR-1 is enriched within the caveolae of adipose cells, normal 
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ERK.112 signaling would occur upon MCH exposure, resulting in leptin transcription. 
Systemically, leptin feedback would turn off the activated MCH signals for the body to 
consume food. As an individual gains excess fat and cholesterol, and thus weight, their 
pre-adipocytes differentiate to become mature adipose (fat) cells. Caveolae accumulates 
in the adipocyte during this process. The normal signaling pathways and functioning of 
the MCH receptor enriched in adipocyte caveolae may become dysregulated at this point 
due to an unknown mechanism. In an overweight individual, this alteration of signaling 
pathways could lead to an absence of satiety due to low leptin levels, loss of the MCH-
leptin feedback loop, and hyperactive MCH secretion by the hypothalamus. This person 
would continue to feel hungry, despite high caloric intake, due to the disruption in leptin 
secretion. Increased hunger inevitably leads to food consumption, an accrual of body 
mass, and an obese body type. 
Further support for MCHR-1 enrichment to lipid rafts 
·Further evidence for the enrichment ofMCHR-1 to lipid rafts arises from the 
primary amino acid sequence of the receptor itself. Somatostatin receptors are known to 
localize to lipid rafts (69), and MCHR-1 was originally identified as orphan GPCR 
SLC-1, or somatostatin-like receptor-I . In addition, preliminary co-immunoprecipitation 
studies currently underway in the lab indicate that a protein complex interaction between 
MCHR-1 and cav-1 is occurring (data not shown). If conclusive, this evidence would 
further support MCHR-1 enrichment to caveolae lipid rafts. 
The finding that MCHR-1 is enriched in lipid rafts provides another attractive 
question - what about other tissues that MCHR-1 has been discovered in? Although this 
thesis seeks to demonstrate that MCHR-1 localizes to the lipid rafts of CHO-Kl cells, 
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MCHR-1 has also been isolated in adipose and pancreatic islet P cells and within the 
brain and central nervous system. Although caveolae are present in adipocytes and 
pancreatic islet p cells (107), caveolae is undetectable in neurons (67). The possibility 
exists that MCHR-1 is present within the lipid rafts of certain cell types, such as pre- and 
mature adipocytes, but not in all MCH receptor-associated cells. This is characteristic of 
receptors that are enriched in, but do not solely localize to, caveolae lipid rafts. 
Proposed peripheral model 
MCH secretion from the hypothalamus begins as a central nervous system 
response that induces peripheral feeding.behaviors. The mechanism that triggers MCH 
release has not yet been elucidated. MCH release also appears to result in energy 
conservation. MCH receptors have been isolated in pancreatic islet p, adipose, CNS, eye, 
tongue, and muscle cells (51,64,65). The discovery ofMCHR-1 in pancreatic islet P cells 
and the presence of the insulin receptor in the caveolae of adipocytes suggest an 
interesting possibility for cross-talk to exist between these two receptors. Previous work 
has suggested that Ca +2 influx precedes insulin secretion in pancreatic islet p cells (88). 
Similarly, MCH administration results in a dose-dependent insulin secretion in p cells 
preceded by Ca+2 release (51). Insulin causes ERK.112 activation, an MCHR-1 GJGq 
coupled response, in adipocytes (84). 
It is possible that low systemic circulating insulin levels prompt MCH release 
in a fasting state. Due to increased levels of MCH, an individual consumes food. 
Circulating MCH binds to the MCH receptors on the pancreatic p cells, causing a Gq 
coupled pathway to become activat~d, which then causes Ca+2 and insulin release. 
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Insulin enters the bloodstream to prepare the cells of the body to take up newly released 
glucose from the meal. Insulin binds to insulin receptors, while MCH binds to MCHR-1, 
both localized to adipocyte caveolae. The insulin receptor, a tyrosine kinase receptor, 
dimerizes and is able to mediate cross-talk with the activated MCH receptor. The body is 
now in a fed state, and activated MCHR-1 couples to 0 0 or Gq; this results in leptin 
transcription. Leptin release from adipocytes results in an overall 'full feeling' once 
leptin binds to its hypothalamic receptor (96), and the individual stops eating. Systemic 
MCH levels then decrease to prevent continued food intake. 
The overweight or obese individual varies from this model in several respects. 
Obesity may result if a person has molecular defects that result in one of the following: 
hyperactive MCH release, failure ofMCHR-1 to elicit the leptin response, or disruption 
of the leptin-MCH feedback mechanism. Too much MCH or too little leptin release may 
cause an individual to continue to consume food, leading to weight gain without feeling 
calorically satisfied. Increased weight is the result of pre-adipocyte accumulation of 
triacylglycerides, causing increases in fat cell size, differentiation, and ultimately cell 
division (74,96). Unfortunately, once an increase in the number of fat cells has been 
achieved, even weight loss does not decrease the number of cells present in an individual. 
As stated previously, increased levels of caveolae within an adipocyte may 
lead to dysregulated MCHR-1 signaling and/or its proposed cross-talk with the insulin 
receptor by an unknown mechanism. Presumably, higher amounts ofERKl/2 activation 
would lead to corresponding increases in leptin transcription in vivo. Systemically, this 
individual would probably feel full and stop eating. However, in an obese individual, 
ERK.112 activation and leptin transcription may be decreased, and MCH and insulin 
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levels would remain high. High insulin may lead to insulin receptor desensitization, and 
the individual would continue eating, propagating and encouraging an obese phenotype. 
This proposed peripheral model offers an explanation as to why obese individuals are at 
risk for type II insulin-resistant diabetes. Weight loss often results in a reversion of the 
condition, restoring cellular responsiveness to insulin. 
Future directions 
There are several potentially promising directions that this project could take. 
First, the characterization of a protein complex interaction between MCHR-1 and cav-1 
by co-immunoprecipitation is critical. Co-immunoprecipitation with cav-1 is one of the 
accepted methods for establishing enrichment within caveolae (20,32). This experiment 
could be performed on isolated caveolae fractions containing the MCH receptor. If such 
a protein interaction were to be discovered, it would provide substantial evidence for the 
enrichment ofMCHR-1 to caveolae lipid rafts. Second, the use of an endogenous cell 
line, such as the 3T3-Ll pre-adipocyte or differentiated adipocyte, is critical for assessing 
the functional role of MCHR-1 in adipocyte caveolae. Third, the use of siRNA to delete 
caveolin-1 solely rather than pharmacological cholesterol depletion, which may have 
possible side-effects unrelated to receptor signaling, is advised as well. This method will 
better assess the consequences of caveolar loss on MCHR-1 signaling and functioning. 
Fourth, the use of MCHR-1 inhibitors in combination with signaling assays 
for cAMP or Ca +2 may be used to further determine the consequences of signal alteration 
due to caveolae disruption in an endogenous system. Fifth, evaluation of leptin 
transcription levels at various MCH .exposure time points with and without caveolae lipid 
raft disassembly would provide further supporting evidence for caveolar regulation of 
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MCHR-1. Sixth, the use of electron microscopy with immunogold labeling towards 
MCHR-1 in 3T3-Ll cells to localize the receptor to caveolae would be highly appealing, 
and may provide more detailed evidence than immunocytochemical studies alone. 
Finally, further analysis of the possible cross-talk between MCHR-1 and the insulin 
receptor could be pursued to establish molecular and physiological connections between 
both of these important metabolic mediators. 
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CONCLUSION 
Investigation into MCHR-1 and lipid raft regulation of receptor functioning is 
important for several reasons. First, the MCHR-1 pathway provides a promising target 
for pharmacological drug development towards fighting the obesity epidemic. However, 
knowledge of this receptor and its signal transduction mechanism must first be elucidated 
before drug targeting is possible. Second, the medical and the social impacts of 
uncovering a possible obesity therapeutic are extremely positive, and at this point, 
necessary. The ever-growing global obese population is in desperate need of an answer 
and a hope. Although everyday lifestyle changes such as improved eating habits and 
physical activity allow for incremental weight loss, even these apparently obvious 
adjustments are not enough for some morbidly obese individuals. Molecular and cellular 
disruption of key homeostatic energy and metabolic pathways is also contributory. The 
only answer is to continue the scientific pursuit of appetite hormones, such as MCH and 
associated receptors to provide evidence of, and solutions to, abnormal molecular 
functioning as an underlying cause of obesity. 
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APPENDIX I: Introductory Figures 
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Figure 1. Central nervous regulation of peripheral hormone responses (previously 
published, 3). Appetite signals are initially released by peripheral tissues, and are 
received by the hypothalamus. The hypothalamus then reacts by secreting additional 
hormones that prompt an individual to eat. Peripheral responses are generated by 
gastrointestinal organs, such as the large intestine and the stomach, and by metabolic 
regulators, such as adipose tissue and pancreatic islet ~ cells, that loop back to the brain 
to shut off the hunger signal. 
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Figure 2. G protein-coupled receptor signaling pathways involving Gv,, G0 , and Gq. 
Coupling of GPCRs to Gs stimulates the adenylyl cyclase pathway, while Gi inhibits 
adenylyl cyclase and its downstream signaling components cyclic AMP ( cAMP) and 
protein kinase A (PKA). The G0 pathway activates protein kinase C (PKC) and the 
Ras/Raf MAPK cascade. Gq leads to phospholipase C (PLC), inositol triphosphate (lP3) 
and diacylglycerol (DAG) activation, followed by calcium (Ca+2) release. 
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Figure 4. Clathrin-coated vesicles and caveolae differ in characteristic morphology, 
as shown by electron microscopy. A) Clathrin-coated pits (previously published, 6) 
assemble into a lattice, creating clathrin-coated vesicles (CCV s) with the help of adaptor 
proteins, such as the AP-2 complex and dynamin (6,10,13). These pits 'pinch off' from 
the plasma membrane, with their molecular cargo secured inside the formed vesicle (10). 
B) Caveolae are distinguished by forming invaginations along the plasma membrane 
(previously published, 32). Lipid rafts are lipid- and cholesterol-rich regions of the 
plasma membrane. An abundance of signaling molecules and membrane proteins 
sequester within these areas. 
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Figure 5. The mammalian MCH peptide is 19-amino acids in length with two 
additional and four substituted residues (adapted, 46). The primary amino acid 
sequence of the MCH cyclic neuropeptide varies between the mammalian and the fish 
homologues. The dicysteine bridge forms the essential ring structure between residues 
Cys7 and Cys16 in the mammalian MCH peptide (Cys4 and Cys13 in fish). The 
mammalian MCH variant (shown) has an additional N-terminal aspartate (Asp1) 
phen~lalanine (Phe2) and with substitutions at methionine (Met4), leucine (Leu\ leucine 
(Leu), and glutamine (Gln18). The fish MCH peptide homologue is 17-amino acids in 
length, differing from the mammalian MCH with variable amino acids at threonine 
(Thr4), methionine (Met\ valine (Va19) , and glutamate (Glu18) (not shown). 
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Figure 6. Post-translational processing of the MCH preprohormone (pMCH) gene 
in humans results in multiple protein products (previously published, 43). MCH is 
only one of three peptides that may be encoded by the second and third exons of the 
pMCH gene. Neuropeptide E-I (NEI) and neuropeptide G-E (NOE) are also potential 
gene products. NEI has been shown to stimulate systemic effects that are antagonistic to 
MCH, such as inhibiting feeding behaviors. pMCH is found on chromosome 12 (12q23-
24). 
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Figure 7. The ob-/ob-MCH-1- mouse demonstrates an overall reductiofl in body fat 
and adiposity compared to the leptin deficient ob-lob- mouse (previously published, 
50). The ob-lob- MCI11- mouse (right) exhibits hyperphagic behavior, similar to that of 
the obese ob-lob- mouse (left). Increases in resting metabolism, body temperature, and 
physical activity characterize the ob-lob- MCH"1- mouse. Improvements in glucose 
tolerance and insulin sensitivity were also noted. 
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Figure 8. MCH regulates hypothalamic feeding responses and insulin secretion 
· from pancreatic islet p cells (previously published, 51 ). Mice with unregulated pMCH 
expression show increases in both feeding behaviors and pancreatic ~ cell mass with 
insulin resistance and hyperglycemia. Mice lacking the functional pMCH gene 
demonstrate decreases in feeding and insulin secretion with hypoglycemia. 
Hypothalamus 
~~ 
t ~':c(..~1:"~' C:±:) feed,i~g · 1 ~ '  ~ ~ 
-'\.... /. · ~'..':} Hyperglycemia 
MCH . -. " 
Overexpressor 0--- ~ / 
·~ .. _ fl:~ell ~ass c=:::> Insulin secretion 
MCH Knockout ~ ~ 
'\. ... Hypoglycemia 
-......._ !feeding / 
<::0-........__ :-."'·,~T~' :~ Hypothala~~ 
56 


l 
I 
I 
I 
I 
I 
I 
I 
I 
Figure 11. ~ICHR-1 single nucleotide polymorphisms (SNPs) are linked to obesity 
(previously published, 67). The MCHR-1 gene contains a I-kb promoter with a 3.5-kb 
coding region. Seven of the 39 MCHR-1 SNPs were identified as encoding for single 
amino acid substitutions. R248Q has been associated with early onset extreme obesity. 
The remaining six SNPs (shown below) were characterized in an obese population of 557 
adults and 552 children. Dominant linkages were found between the SNPs and obesity. 
SNP rsl33068 has been shown to provide protection against childhood obesity. 
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Figure 2. VSVg-MCBR-1 co-localizes with caveolin-1 enriched fractions, as 
demonstrated by fractionation and western blotting. VSVg- MCHR-1 CHO-Kl cells 
were cultured to confluency, and caveolae membranes were isolated using a detergent 
free sucrose gradient ultracentrifugation method as previously described (93) with 
modifications. Fractions were collected and separated by 12% SDS-PAGE. A) Western 
blotting was performed using rabbit anti-VSV g (1 :2000, Sigma) and rabbit anti-caveolin 
(1:5000, BD Biosciences) antibodies.1 VSVg-MCHR-1 and cav-1 co-localize.in fractions 
4 and 5. B) A Bradford assay assessed total protein of each fraction. Cellular protein 
content peaks at fraction 5, following caveolae isolation. 
Isolated Fraction 
2 3 4 5 6 7 8 9 10 11 12 
A) I :1 I .. 1£!Q;!_ VSVo-MCHR-1, ......... • ~. 
~ 
.c.:i - -17-kOa 
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:::;-
~ ~ 
c 0.15 
.! 
c 
0 
" c 0.1 ~ 
a. 
0.05 
0 
1 2 3 4 5 6 7 8 9 10 11 12 
Fractioo 
1 Western blots were assisted by Kelsi Robinson, B.S. 
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Figure 3. MCHR-1 localization to caveolae enriched fractions is independent of 
1.0-µ.M MCH treatment at 10-minutes with equal protein loading. VSV g-MCHR-1 
CHO-Kl cells were cultured to confluency, and exposed to 1.0-µM MCH in F12k- media 
for 0- or 10-minutes as indicated. Caveolae membrane microdomains were isolated using 
a detergent-free sucrose gradient ultracentrifugation method as previously described (93) 
with modifications. Fractions were collected from each gradient, and a Bradford assay 
was performed. Equal protein (approximately 100-ng) from fractions 4, 5, 6, and 7 for 
each treatment was loaded onto 10% SDS-PAGE gels. Western blotting was performed 
using rabbit anti-VSV g (1 :2000, Sigma) and rabbit anti-caveolin (1 :5000, BD 
Biosciences) antibodies. The majority of cellular VSV g-MCHR-1 and cav-1 continue to 
localize to fraction 4 with MCH exposure. 
Isolated Fraction 
0-min. MCH exposure 10-min. MCH exposure 
4 5 6 7 . 4 5 6 7 
.vSVg-MCHR-1 
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Figure 4. MCHR-1 localization to caveolae lipid raft fractions is independent of 
1.0-p.t.M MCH exposure across time points2, as shown by sucrose-density gradient 
isolation and western blotting. VSVg-MCHR-1 CHO-Kl cells were cultured to 
confluency, and exposed to 1.0-µM MCH in F12k- media for the time points indicated. 
Caveolae membrane microdomains were isolated using a detergent-free sucrose gradient 
ultracentrifugation method as previously described (93) with modifications. Fractions 
were collected from each gradient. A) Samples were run on 10% SDS-PAGE gels, and 
western blotting was performed using rabbit anti-VSV g antibody (1 :2000, Sigma) 
towards VSVg-MCHR-1. At 0-minutes MCH exposure, VSVg-MCHR-1 localizes to 
fractions 4 (arrow) and 5. The majority ofMCH receptor localizes to fraction 4, with a 
molecular weight upshift ofMCHR-1infraction5 following 5- and 10-minutes MCH 
exposure (arrows). At 30-minutes MCH exposure, receptor returns to fraction 5, and the 
molecular weight upshift is absent (arrow). B) Samples were run on 12% SOS-PAGE, 
and western blotting was performed using rabbit anti-caveolin (1 :5000, BD Biosciences) 
antibody towards cav-1. Cav-1 co-localization with MCHR-1 is evident in fractions 4 
and 5 at 0-minutes, in fractions 4, 5, and 6 at 5-minutes, in fractions 5 and 6 at 10-
minutes, and in fraction 5 at 30-minutes MCH exposure. 
Isolated Fraction 
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2 Sucrose gradient performed by author and Laurie Cook, Ph.D. (Pl). 
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Figure 5. MCHR-1 localization to caveolae is independent of 1.0-µM MCH 
exposure across time points, as shown by Bradford assay. A Bradford assay was 
performed on the isolated fractions3• A) Combined sucrose gradient profile for 0-, 5-, 
10-, and 30-minutes MCH exposure. B) Sucrose gradient profile at 0-minutes MCH 
exposure. Caveolae peaks at fraction 4. C) Sucrose gradient profile for 5-minutes MCH 
exposure. Caveolae peaks at fraction 5. D) Sucrose gradient profile for IO-minutes 
MCH exposure. Caveolae peaks at fraction 5. E) Sucrose gradient profile for 30-minutes 
MCH exposure. Caveolae peaks at fraction 5. 
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Figure 6. Manipulation of membrane cholesterol alters the distribution ofMCHR-1 
in stably transfected CHO-Kl cells4• VSVg-MCHR-1 CHO-Kl cells were grown to 
partial confluency on coverslips. Cells were serum starved I-hour prior, treated with 5.0-
mM methyl-~-cyclodextrin (M~CD; Sigma) or 1.0-mM soluble cholesterol (Sigma) for 1-
hour, and then exposed to 1.0-µM MCH for the indicated times during incubation. 
lmmunocytochemistry was performed using mouse anti-VSV g ( 1: 1000, Sigma) and 
donkey anti-mouse Cy3 (1:500, Jackson Labs) antibodies. DAPI (1-µg/mL, Roche) was 
applied, and coverslips were washed and mounted with Pro Long Gold (Invitrogen) on 
blank slides. Images were taken with the structured light imaging OptiGrid confocal 
microscope using ImagePro Plus software. A) Cholesterol depletion with M~CD alters 
the morphology ofVSVg-MCHR-1 CHO-Kl cells significantly. Cell membranes are 
observed to be severely deformed. B) Loading with soluble cholesterol causes MCHR-1 
redistribution to cellular areas surrounding the nucleus, possibly endoplasmic reticulum 
(ER), following MCH exposure. 
A) 
B) 
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0 
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MCH exposure 
0-min. 30-min. 
4 Immunocytochemistry and imaging performed by Kelsi Robinson, B.S. 
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60-min. 
Figure 7. Cholesterol depletion with methyl-1}-cyclodextrin dampens MCH-
dependent ERK 1/2 activation5. CHO-Kl cells were grown to confluency in a 12-well 
dish, and transiently transfected with untagged MCHR-1 plasmid (UMR cDNA Resource 
Center). Cells were serum starved in F12k- media for I-hour prior to harvesting, then 
received 10.0-mM methyl-P-cyclodextrin or Fl2k-alone for I-hour as indicated. MCH 
(1.0-µM) was added for the designated time points. Cells were washed with Ix PBS on 
ice, harvested in 50-µL, 2x Laemelli buffer, and run on 12% SDS-PAGE. A) Western 
blotting was performed using mouse anti-P-MAPK p42/44 (1: I 000, Cell Signaling) 
antibody toward activated ERKl/2 and rabbit anti-MAPK p42/44 (1 :1000, Cell 
Signaling) antibody toward total ERKl/2. ERKI/2 is activated following 5-minutes, and 
sustained through I 0-minutes MCH exposure in control cells. From the western blot, the 
ERKI/2 response appears at 5-minutes, and is prolonged up to 30-minutes MCH 
exposure in the MPCD-treated cells. B) Densitometry was performed using Adobe 
Photoshop software. Total ERKI/2 levels from control cells are reported as the baseline 
(1.0 relative units). In control cells, ERK.1/2 phosphorylation peaks at 5-minutes and 
declines at 10-minutes MCH exposure. MCH-dependent ERKl/2 activation is dampened 
at 5-minutes and peaks at I 0-minutes MCH exposure following cholesterol depletion 
with MPCD, as shown. 
A) 
Control . M@CD 
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,P=ERK 112 
B) ERK 112 Activation Following Cholesterol Depletion with MPCD 
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5ERK1/2 activation with M~CD experiments performed by author and Laurie Cook, Ph.D. Transient 
transfection and densitometry (for this blot) were performed by Dr. Cook. 
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G-418 
l) 0.5-mg/mL G-418 (A.G. Scientific) in sterile dH20 
2) Filter sterilize. 
1 Ox Phosphate-buffered saline (PBS) 
To approximately 800-rnL dH20, add: 
80-g NaCl 
2-gKCl 
14.4-g Na2HP04 
2.4-g KH2P04 
pH to 7.4 with 10-N NaOH, then bring to 1-L with the necessary volume of dH20. 
PBS-T 
1 x PBS with 0.1 % Tween-20 
Methyl-P-cyclodextrin (MPCD) stock solution 
1) 0.50-g/mL (Sigma) in sterile dH20 
2) Filter sterilize. 
Soluble cholesterol stock solution 
1) 0.39-g/mL Soluble cholesterol (Sigma) in sterile dH20 to achieve 100-mM stock 
2) No need to filter sterilize. 
5x Bradford reagent 
1) Dissolve 100-mg Coornassie blue (90%) in 50-mL ethanol 
2) Add 100-mL, 85% Phosphoric acid 
3) Add 50-mL dH20 
4) Gravity filter. 
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Mes-buffered saline (MBS) 
25-mM Mes (Acros Organics) 
0.15-MNaCl 
pH to 6.5 
90% Sucrose gradient 
45-g Sucrose 
Bring to 50-mL with the necessary volume of MBS. 
35% Sucrose gradient 
35-g Sucrose 
Bring to 100-mL with the necessary volume of MBS with 250-mM Na2C03, pH 11. 
5% Sucrose gradient 
5-g Sucrose 
Bring to I 00-mL with the necessary volume of MBS with 250-mM Na2C03, pH 11. 
2x Sample buffer by Hoeffer Scientific (prepare under fume hood) 
2.5-mL, 0.5-M Tris HCI, pH 6.8 
4.0-roL, 10% SDS 
2.0-mL Glycerol 
1.0-mL Concentrated 2-mercaptoethanol 
0.4-mg Bromophenol blue 
Bring to I 0-mL with the necessary volume of d.H20. 
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5x Laemelli sample buffer (prepare under fume hood) 
3.75-mL, 1.0-M Tris HCl, pH 6.8 
1.5-g SDS 
0.075-g Bromophenol blue 
1.16-g Dithiothreitol (Cleland's reagent) 
Bring to 7.5-mL with the necessary volume of dH20. Add 7.5-mL glycerol. 
1 Ox SDS running buffer 
For 1-L in dH20: 
30.3-g Tris base 
144-g Glycine 
10-g SDS 
Semi-dry transfer buffer 
To 250-mL of dH20, add: 
5.8-g Tris base 
2.9-g Glycine 
0.37-g SDS 
200-mL Methanol 
Bring to 1-L with the necessary volume of dH20. 
1 Ox Tris-buffered saline (TBS) 
87.66-g NaCl 
12.11-g Tris base 
4-mLHCl 
pH to 8.0, then bring to 1-L with the necessary volume of dH20. 
TBS-T 
1 x TBS with 0.1 % Tween-20 
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SDS-PAGE gels (10-12%) 
A) 10-12 % Rururing gel, B) 4% Stacking gel. 
Percentage 10% 12% 
A) 7.5-ml 10.0-ml 5.0-ml. 10.0-ml. 
40% Bis-acryl 1.875-ml 10.0.ml 1.5-ml 3.0-ml 
4x Tris-Cl/SOS, 1.875-ml 2.5-ml 1.25-ml 2.5-ml 
pH8.8 
dtip 3.75-ml 5.0.ml 2.23-ml 4.46-ml 
10% APS 25.0.µL 33.0.µL 16.7-µL 33-µL 
TE MED 5.0.µL 6.6-µL 3.3-µL 6.6-µL 
Percentage 4% 
B) 2.1-ml 1.0-ml 15.0-ml 
40% Bis-acryl 244-µL 4M-µL 1.464-ml 
4Jt Tris-Cl/SOS, 625-µL 1.25-ml 3.75-ml 
pH6.8 
dtip 1.61-ml 3.21 -ml 9.63-ml 
10% APS 12.5-µL 25-µL 75.0.µL 
TE MED 2.5-µL 5.0.µL 15.0.µL 
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